Ass-thma (Chronic) Flashcards
(44 cards)
SABA agents for asthma
- albuterol
- levalbuterol - more potent
ICS agents for asthma
- Ciclesonide
- Fluticasone - higher risk of sore throat/hoarseness
- Beclomethasone - smaller particles → better lung penetration
- Mometasone
- Budesonide
LABA agents for asthma
- Salmeterol
- Formoterol
- Vilanterol
LAMA agents for asthma
- Tiotropium
Leukotriene modifiers for asthma
Leukotriene D4 antags
- Montelukast
- Zafirlukast - DDI warfarn, theophylline
5-lipooxygenase inhibitor
- Zileuton - DDI theophylline
Biologics for asthma
- Omalizumab
- Mepolizumab
- Reslizumab
- Benralizumab
- Dupilumab
SABA application in asthma therapy
- short acting beta agonists
- Rescue therapy
Inhaled corticosteroid application in asthma therapy
First line maintenance - dosed BID (except for Arnuity QD and mometasone QD OR BID)
AVOID in aute bronchospasm and status asthmaticus
LABA application in asthma therapy
- long acting beta agoists
Maintenance therapy - must be used in COMBO with ICS ← has a BBW of asthma-related death if used as monotherapy
ICS/formoterol (speficially, budesonide/formoterol), can be used as a rescue
LAMA application in asthma therapy
Maitenance therapy
Leukotriene modifier application in asthma therapy
Maintenance for persistent asthma
If using montelukast for exercise, take 2hrs prior
Theophylline application in asthma therapy
Not frequetly used d/t high risk of AE, DDI (CYP3A4), and narrow window (5-15mcg/mL)
- also less effective than ICS
Biologics application in asthma therapy
- In pts with severe allergic or eosinphilic asthma
- Admined in healthcare setting
SABA MOA
stimulate beta 2 receptor in lungs → relaxation of bronchial smooth muscle → bronchodilation (does NOT address inflammation)
Inhaled corticosteroid MOA (asthma)
- Reduce chronic airway inflammation; decrease airway hypersensitivity
- Reduce risk of exacerbations → reduced hospital admissions and death
- Improve lung function → peak expiratory flow rate increases
- Reduce symptoms
LABA MOA
stimulate beta 2 receptor in lungs → relaxation of bronchial smooth muscle → bronchodilation (does NOT address inflammation)
- same as SABA
LAMA MOA
Inhibit the action of ACh at the M3 muscarinic receptor in bronchial smooth muscle → bronchodilation
Leukotriene modifiers MOA (asthma)
Block pro-inlammatory leukotrienes at receptor sites → reduce airway constriction and mucus secretion
Theophylline MOA
Block phosphodiesterase, increase cAMP → release of epinephrine from adrenal medulla cells → brochodilation, CNS and cardiac stimualtion, diuresis, gastric acid secretion
Caffeine is an active metabolite
Biologics for asthma MOA
Targets
- IgE: allergic response
- IL-4: inflammation
- IL-5: eosinophils
SABA AE
- Tremor, shakiness
- Lightheadedness
- Cough
- Palptations
- Hypokalemia
- Tachycardia
- Hyperglycemia
Inhaled corticosteroids for asthma AE
USE LOWEST DOSE POSSIBLE
- step down when asthma is well controlled, decrease dose 25-50% after 3 months of stability
Oropharyngeal candidiasis
Dysphonia
Growth concerns in children (not clinically significant)
Hyperglycemia
Increased risk of fractures
Leukotriene modifiers for asthma AE
- HA
- URI
- GI
- Psych - montelukast only
- aggressive behavior
- AMS
Theophylline AE
Nausea
Loose stools
HA
Tachycardia
Insomnia
Tremor, Nervousness
AVOID in: CV hx, hyperthyroid, PUD, seizures